J

Johnson & Johnson

Makes prescription drugs and medical devices

Brand Manager R/R Multiple Myeloma

Full-TimeUpdated on 10/15/2026Deadline 10/30/26
PLN205k - PLN354.2k+ Annual bonus + Sales commissions
Mid
Bachelor's
Warsaw, Poland
HybridOffice-based role with frequent travel in Poland and abroad.
Growth & MarketingBrand & Creative Marketing

About the job

Requirements
  • A university degree in a relevant field, such as economics, business, or life sciences; a major in marketing is preferred.
  • At least 3 years of product and/or brand management experience within the pharmaceutical business.
  • Proven experience using omnichannel engagement and digital tools.
  • A proven track record orchestrating cross-functional teams in a competitive environment.
  • Experience in the hospital market and drug programs.
  • A high level of project management capability.
  • Strategic thinking and understanding of how individual contributions support business success at local and regional levels.
  • Ability to solve problems structurally and handle stress and difficult situations.
  • Persistence in the face of obstacles or challenges.
  • High ethical standards in business.
  • Native fluency in the local language and fluent spoken and written English.
  • Availability for frequent travel in Poland and abroad.
Responsibilities
  • Develop commercial tactics and messaging plans to achieve product performance targets, including net sales and market share, and ensure local brand positioning aligns with EMEA strategy and approved product indications.
  • Monitor local brand performance and provide standard key performance indicators and metrics in collaboration with relevant stakeholders.
  • Lead implementation of segmentation, targeting, channel, and marketing-mix strategies based on customer needs, and maintain relevant customer information in iConnect and other tools.
  • Develop and lead business plans to meet future needs and expectations, and ensure their execution.
  • Protect brand integrity through cross-functional and cross-channel efforts.
  • Implement tactical plans by providing promotional materials and using appropriate marketing-mix elements and communication channels.
  • Monitor compliant spending of the promotional investment budget.
  • Work productively with external agencies and internal cross-functional groups.
  • Ensure completion of market analysis and monitor competitive activity.
  • Build a network with key opinion leaders and monitor industry developments affecting the business.
  • Develop innovative marketing programs based on brand and product strategies and implement them through staff.
  • Coach and train junior or new colleagues in techniques, processes, and responsibilities.
  • Integrate Johnson & Johnson’s Credo and Leadership Imperatives into team goals and decision-making.
  • Plan, gather insights for, and execute market research.
  • Perform business planning, including financial forecasting, product sheets, marketing-mix analysis, strategic planning, and brand deep-dives.
  • Develop partnerships with medical societies, opinion leaders, consumers, patients, clients, and other enterprises to deliver key projects.
  • Lead and coordinate Country Value Team members, plan and facilitate meetings, and ensure members follow up on assigned actions.
  • Align Country Value Team members on brand strategy, value proposition, objectives, tactical plans, and financial plans.
  • Communicate and align brand strategy with the Integrated Brand Value Team, regional hubs, and stakeholders.
  • Meet safety-reporting requirements, including timely adverse-event and product-quality-complaint reporting, in accordance with company policies and standard operating procedures when planning projects, developing materials, executing projects, and contracting vendors.
  • Understand and comply with healthcare compliance and legal requirements, including fair market value, transfer-of-value rules, and promotional-material rules.
  • Maintain high standards of ethics, quality, compliance, and accountability; complete compulsory training on time and help others meet the Quality & Compliance Core Objective when appropriate.
  • Interact with key opinion leaders and key stakeholders to build and monitor company and brand loyalty.
  • Lead development and execution of short- and long-term brand-management strategy, provide insights on market performance and product trends, drive product development, and use analytics and reporting to develop go-to-market strategies for new products.
  • Execute brand-management strategy using a customer-centric approach that incorporates research and development innovations; create presentations and reports on key performance indicators and market complexity; and incorporate industry best practices into recurring processes.
  • Collaborate with Medical Affairs, Market Access, Business Intelligence, and sales and marketing teams to identify opportunities through assessment of market trends, customer needs, and competitive activity.
  • As Country Value Team Leader, lead development and cross-functional execution of integrated brand and therapy-area strategy across marketing, sales, medical, and market-access workstreams; align the team and business enabler functions, ensure compliance with local policies and regulations, coordinate cross-functional projects, and align with Therapy Area Teams and internal stakeholders.
  • Plan and execute Launch Excellence for new products at customer level.
  • Represent the brand locally and connect country perspectives with the EMEA Strategy Organization; work with the Integrated Brand Value Team and above-country hubs to develop and execute robust regional brand strategy, localize the EMEA brand value plan, and align with EMEA guidelines.
Desired Qualifications
  • Knowledge of the relevant therapy-area portfolio is an additional asset.
  • Preferred skills include brand marketing, brand positioning strategy, business storytelling, customer centricity, customer intelligence, data analysis, data-driven decision-making, developing others, digital strategy, execution focus, financial analysis, inclusive leadership, industry analysis, leadership, product development lifecycle, product management, product portfolio management, product strategies, resource allocation, stakeholder management, and strategic thinking.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.

CNBC
Oct 13th, 2026
J&J beats estimates and lifts forecast to $101.2B, but Middle East conflict hurts device sales

Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.